

NCT ID	NCT05652894
Title	A Study of HX008 Compared to Chemotherapy in the First-Line Treatment of Subjects With MSI-H/dMMR Metastatic Colorectal Cancer
Phase	Phase 3
Date Added	2022-12-15
Location	China
Prior IO Allowed	No
CRC-directed	Yes
Status	Not yet recruiting
Drugs	HX008, Investigator's Choice Chemotherapy
Tags	MSI-H/ MMRd
<hr/>	
NCT ID	NCT05672316
Title	Botensilimab, Balstilimab and Regorafenib for the Treatment of Patients With Microsatellite Stable Metastatic Colorectal Cancer Who Have Progressed on Prior Chemotherapy
Phase	Phase 1
Date Added	2023-01-05
Location	California, United States
Prior IO Allowed	No
CRC-directed	Yes
Status	Active, not recruiting
Drugs	Balstilimab, Botensilimab, Regorafenib
Tags	MSS/ MMRp
<hr/>	
NCT ID	NCT05673148
Title	Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, The ERASur Study
Phase	Phase 3
Date Added	2023-01-06

Location	Arizona, United States California, United States Delaware, United States District of Columbia, United States Florida, United States Georgia, United States Idaho, United States Illinois, United States Iowa, United States Kentucky, United States Maryland, United States Michigan, United States Minnesota, United States Mississippi, United States Missouri, United States Montana, United States Nebraska, United States Nevada, United States New Hampshire, United States New Jersey, United States New Mexico, United States New York, United States North Dakota, United States Ohio, United States Oklahoma, United States Pennsylvania, United States South Dakota, United States Tennessee, United States Texas, United States Utah, United States Washington, United States Wisconsin, United States
Prior IO Allowed	No
CRC-directed	Yes
Status	Recruiting
Drugs	Chemotherapy
Tags	MSS/ MMRp
NCT ID	NCT05677113
Title	A Study of QBECO Versus Placebo in the Treatment of Colorectal Cancer That Has Spread to the Liver
Phase	Phase 2
Date Added	2023-01-10
Location	Canada
Prior IO Allowed	No
CRC-directed	Yes
Status	Recruiting
Drugs	Placebo, QBECO
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT05676190
Title	Clinical Study on the Efficacy of Autologous Cell Factor Induced Killer Cells in the Treatment of Colorectal Cancer
Phase	Not Applicable
Date Added	2023-01-09
Location	China
Prior IO Allowed	No
CRC-directed	Yes
Status	Recruiting
Drugs	

Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT05608044
Title	A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer Without Liver Metastases
Phase	Phase 2
Date Added	2022-11-08
Location	Arizona, United States California, United States Colorado, United States Delaware, United States Florida, United States Massachusetts, United States Michigan, United States New Jersey, United States New York, United States Ohio, United States Oregon, United States Rhode Island, United States Tennessee, United States Texas, United States Virginia, United States Washington, United States Belgium Brazil France Georgia Italy Russian Federation Spain
Prior IO Allowed	No
CRC-directed	Yes
Status	Active, not recruiting
Drugs	Balstilimab, Botensilimab, Regorafenib, TAS-102
Tags	MSS/ MMRp
NCT ID	NCT05609370
Title	A Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Capecitabine Versus Bevacizumab Plus Capecitabine in Participants With Unresectable or Metastatic Colorectal Cancer
Phase	Phase 1, Phase 2
Date Added	2022-11-08
Location	Alaska, United States Arizona, United States California, United States Florida, United States Indiana, United States Kentucky, United States Louisiana, United States Missouri, United States Montana, United States Nevada, United States New Mexico, United States New York, United States North Carolina, United States Tennessee, United States Texas, United States Virginia, United States Washington, United States Australia China Puerto Rico
Prior IO Allowed	No

CRC-directed	Yes
Status	Active, not recruiting
Drugs	Bevacizumab, capecitabine, LBL-007, Tislelizumab
Tags	MSS/ MMRp
NCT ID	NCT05425940
Title	Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer (STELLAR-303)
Phase	Phase 3
Date Added	2022-06-21
Location	Alabama, United States Arizona, United States California, United States Connecticut, United States Florida, United States Georgia, United States Illinois, United States Indiana, United States Kansas, United States Kentucky, United States Louisiana, United States Missouri, United States Montana, United States Nebraska, United States New Mexico, United States New York, United States North Carolina, United States Ohio, United States Oklahoma, United States Oregon, United States Pennsylvania, United States South Carolina, United States Tennessee, United States Virginia, United States Washington, United States Australia Belgium France Germany Hong Kong Hungary Korea, Republic of New Zealand Poland Portugal Singapore Spain Taiwan Thailand United Kingdom
Prior IO Allowed	No
CRC-directed	Yes
Status	Active, not recruiting
Drugs	Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody, Regorafenib, XL092, Stivarga, Tecentriq
Tags	MSS/ MMRp
NCT ID	NCT05627635
Title	FOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal Cancer
Phase	Phase 1, Phase 2
Date Added	2022-11-25
Location	California, United States

Prior IO Allowed	No
CRC-directed	Yes
Status	Active, not recruiting
Drugs	Balstilimab, Botensilimab, fluorouracil, Leucovorin Calcium, oxaliplatin
Tags	MSS/ MMRp
<hr/>	
NCT ID	NCT05328908
Title	A Study of Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS-102 in Participants With Later-lines of Metastatic Colorectal Cancer
Phase	Phase 3
Date Added	2022-04-14
Location	Arkansas, United States California, United States Connecticut, United States Florida, United States Georgia, United States Idaho, United States Indiana, United States Massachusetts, United States Michigan, United States New Jersey, United States North Carolina, United States Ohio, United States Pennsylvania, United States South Carolina, United States South Dakota, United States Tennessee, United States Texas, United States Virginia, United States Wisconsin, United States Argentina Australia Austria Belgium Canada Chile China Czechia France Germany Italy Japan Korea, Republic of Netherlands Poland Puerto Rico Singapore Spain Sweden Switzerland Taiwan
Prior IO Allowed	No
CRC-directed	Yes
Status	Active, not recruiting
Drugs	Nivolumab-relatlimab FDC, Regorafenib, TAS-102, Lonsurf, Opdivo, Stivarga
Tags	MSS/ MMRp